Aims: The methylation status of the MGMT gene promoter,considered of prognostic significance by enhancing chemosensitivityto alkylating drugs in gliomas and melanomas, wasevaluated in a series of primary melanomas and metastasesof patients treated with different therapies, to identify anycorrelation with the patients’ outcome or response to differenttherapeutic regimens.Methods: Twenty-nine primary melanomas and 74 metastases,collected from 52 patients, were assessed forMGMT gene promoter methylation using a standardmethylation specific PCR-based method. All materials wereformalin fixed and paraffin embedded.Results: One of 29 primary melanomas (3.4%) and 22 of74 metastases (29.7%) showed MGMT gene promotermethylation. MGMT methylation was more frequent invisceral (17/40, 42.5%) than in cutaneous/lymph nodemetastases (5/34, 14.7%) ( p¼0.019). Both disease free(DFS) and overall survival (OS) were significantly longerin patients with methylated metastases ( p¼0.009 andp¼0.007, respectively). No correlations were found amongmethylation, therapeutic regimens and DFS or OS.Conclusions: MGMTmethylation appears to be a late event inthe biological history of melanoma and is more frequentlyseen in visceral metastases. The MGMT gene promotermethylation in metastatic disease is associated with longersurvival, irrespective of therapy. Thus it could be considereda prognostic factor in metastatic melanoma.

Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas / A. M., Cesinaro; Sartori, Giuliana; Migaldi, Mario; L., Schirosi; Pellacani, Giovanni; G., Collina; Maiorana, Antonino. - In: PATHOLOGY. - ISSN 0031-3025. - STAMPA. - 44:4(2012), pp. 313-317. [10.1097/PAT.0b013e328353a0ff]

Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas

SARTORI, Giuliana;MIGALDI, Mario;PELLACANI, Giovanni;MAIORANA, Antonino
2012

Abstract

Aims: The methylation status of the MGMT gene promoter,considered of prognostic significance by enhancing chemosensitivityto alkylating drugs in gliomas and melanomas, wasevaluated in a series of primary melanomas and metastasesof patients treated with different therapies, to identify anycorrelation with the patients’ outcome or response to differenttherapeutic regimens.Methods: Twenty-nine primary melanomas and 74 metastases,collected from 52 patients, were assessed forMGMT gene promoter methylation using a standardmethylation specific PCR-based method. All materials wereformalin fixed and paraffin embedded.Results: One of 29 primary melanomas (3.4%) and 22 of74 metastases (29.7%) showed MGMT gene promotermethylation. MGMT methylation was more frequent invisceral (17/40, 42.5%) than in cutaneous/lymph nodemetastases (5/34, 14.7%) ( p¼0.019). Both disease free(DFS) and overall survival (OS) were significantly longerin patients with methylated metastases ( p¼0.009 andp¼0.007, respectively). No correlations were found amongmethylation, therapeutic regimens and DFS or OS.Conclusions: MGMTmethylation appears to be a late event inthe biological history of melanoma and is more frequentlyseen in visceral metastases. The MGMT gene promotermethylation in metastatic disease is associated with longersurvival, irrespective of therapy. Thus it could be considereda prognostic factor in metastatic melanoma.
2012
44
4
313
317
Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas / A. M., Cesinaro; Sartori, Giuliana; Migaldi, Mario; L., Schirosi; Pellacani, Giovanni; G., Collina; Maiorana, Antonino. - In: PATHOLOGY. - ISSN 0031-3025. - STAMPA. - 44:4(2012), pp. 313-317. [10.1097/PAT.0b013e328353a0ff]
A. M., Cesinaro; Sartori, Giuliana; Migaldi, Mario; L., Schirosi; Pellacani, Giovanni; G., Collina; Maiorana, Antonino
File in questo prodotto:
File Dimensione Formato  
Prognostic significance of MGMT gene promoter methylation.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 171 kB
Formato Adobe PDF
171 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/737678
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact